The company provides civil engineering and construction services for government and private infrastructure projects, and has recently pivoted into the power and clean energy sector following the separation of its real estate division.
The company operates in a highly fragmented, tender-based industry with no discernible cost advantage or switching costs, as evidenced by chronically low returns on capital (3.5%) that fail to meet the cost of capital.
Management has historically struggled to generate value, with EPS declining despite revenue growth. Recent actions include a massive demerger and a pivot to the power sector, alongside significant related-party financial assistance totaling 250 Crores.
The business collapsed as the massive 250 Crore related-party financial assistance proved unrecoverable, effectively hollowing out the balance sheet for the benefit of insiders. While revenue grew, the lack of pricing power and negative cash conversion meant that every new contract drained more liquidity, eventually leading to a solvency crisis. The pivot to the power sector failed to generate returns above the cost of capital, and the market finally de-rated the stock as the gap between reported accounting profits and actual cash flow became an unbridgeable chasm.
RichFakir rates RDB Infrastructure and Power Ltd's business quality as poor — 28/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, RDB Infrastructure and Power Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on RDB Infrastructure and Power Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of RDB Infrastructure and Power Ltd's fair value is about ₹7 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →